Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrex

Drug
ak112
Indication
Non-Squamous Non-small Cell Lung Cancer

Other upcoming events for SMMT

PDUFA DatePDUFA Date: ivonescimab
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for th
Phase 3 ReadoutPhase 3 Topline: A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Ve
Patent ExpiryPatent/Exclusivity Expiry: DIFICID

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrex — SMMT Phase 3 Readout | BioSniper